Federal contractors lost not only wages during the 5-week government shutdown, some of them also lost health insurance; with advances in gene therapy, scientists are beginning to talk about a cure in sickle cell disease; there’s bipartisan interest in attacking the issue of unexpected medical bills, and the effort has been aided by President Donald Trump, who voiced support last week for protecting patients.
Federal contractors lost not only wages during the 5-week government shutdown, some of them lost health insurance, The Washington Post reported. The paper detailed how 1 government contractor was unable to pay the $60,000 premium to CareFirst BlueCross BlueShield, leaving employees and their families, some of whom have delayed medical care, with financial liabilities.
With advances in gene therapy, scientists are beginning to talk about a cure in sickle cell disease, The New York Times reported. In a half-dozen clinical trials planned or underway, researchers are testing strategies for correcting the problem at the genetic level. While a handful of the enrolled patients no longer show signs of the disease, it is still early in the course of these experimental treatments, and it is likely to be at least 3 years before one is approved.
There’s bipartisan interest in attacking the issue of unexpected medical bills, and the effort has been aided by President Donald Trump, who voiced support last week for protecting patients, The Hill reported. The effort faces obstacles from powerful healthcare industry groups, which want to ensure that they avoid a financial hit from whatever solution lawmakers and the White House put forth.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Report Reveals Mounting Burdens of Drug Shortages on US Health System
June 27th 2025Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard and labor costs soaring—but the true impact may go far beyond limited medication access, threatening to disrupt the very foundations of how health systems operate.
Read More